

# CEN TOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: N1976T109 Asset Class: **Stock**

<b>Company</b>	2024/08/07 22:00:00
<b>Price</b>	<b>0.33</b> USD
<b>Difference</b>	📉 -6.23% (-0.02)



## Contact Details

CEN TOGENE NV Tel: +49-381-80113400  
 -- Fax: +381-80113401  
 Am Strande 7 Web: <http://www.centogene.com>  
 18055 Rostock E-mail: -

## Company Profile

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	48,625,000		63,855,000		58,539,000	
<b>Common stock capital</b>		3,841,000		3,529,000		3,079,000
<b>Fixed assets</b>	36,603,000		35,197,000		44,597,000	
<b>Equity capital of a company</b>		-27,927,000		7,909,000		31,276,000
<b>Cash and cash equivalents</b>	21,097,000		38,368,000		20,262,000	
<b>Accrued liabilities</b>		435,000		277,000		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		47,904,000		26,323,000		44,914,000
<b>Prepayments and accrued income</b>		-		-		-
<b>Non-current liabilities</b>		58,955,000		57,683,000		17,816,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		320,000		616,000		0
<b>Total assets</b>	85,229,000	85,229,000	99,053,000	99,053,000	103,137,000	103,137,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	493	517	808
<b>Equity ratio</b>	-32.77%	7.98%	30.54%
<b>Debt-equity ratio</b>	-405.18%	1,152.35%	227.46%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	-0.82%	-0.28%	0.05%

# CENTOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: N1976T109 Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	52,473,000	49,892,000	224,485,000
<b>Net income</b>	-38,414,000	-40,675,000	-55,494,000
<b>EBIT</b>	-26,500,235	-33,481,904	-49,480,636
<b>Operating income before taxes</b>	-37,777,000	-40,563,000	-55,406,000
<b>Cash Flow</b>	-40,796,000	-32,997,000	-26,007,000
<b>Net interest income</b>	-8,640,000	-3,749,000	-1,002,000
<b>Research and development expenses</b>	11,221,000	15,303,000	18,198,000
<b>Income taxes</b>	310,000	112,000	-28,000
<b>Result from investments in subsidiaries, associates and other</b>	-326,000	0	0
<b>Revenues per employee</b>	96,804	87,771	252,685

## Board of Directors

Peer Schatz	Chairman of Supervisory Board
Eric Sou�tre	Member of Supervisory Board
Hubert Birner	Member of Supervisory Board
Jonathan Sheldon	Member of Supervisory Board
Guido Prehn	Member of Supervisory Board
Mary Sheahan	Member of Supervisory Board

## Members of Management Board

Kim Stratton	Chairman of Managing Board
Ian Rentsch	Member of Executive Committee
Miguel Coego Rios	Member of Executive Committee
Peter Bauer	Member of Executive Committee